Answers are grounded in this paper and cite their sources.
We report our experience during COVID-19 outbreak for intravitreal injections in patients with maculopathy. We proposed a treatment priority levels and timings; the "High" priority level includes all monocular patients; the "Moderate" is assigned to all patients with an active macular neovascularization; the patients affected by diabetic macular edema or retinal vein occlusion belong to the "Low" class. This organization allowed us to treat the most urgent patients although the injections performed had a 91.7% drop compared to the same period of 2019.
No takes yet. Share an insight, caveat, or question.
Carnevali et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: